CME Webinar: The State of Telehealth in 2026

Dec. 2025Education/Webinars

Please join us for a live, CME-accredited webinar on Tuesday, Jan. 27, from noon to 1 p.m. that will share updates on the state of telehealth for 2026.

During this webinar, our presenters will:

  • Describe the current state of telehealth and how payers and providers are using it.
  • Explain telehealth services offered and utilization trends at UPMC.
  • Apply knowledge of the regulatory challenges facing the industry to clinical practice.

Speakers:

  • Andrew Watson, MD, Mlitt FACS FATA, Professor of Surgery, Colorectal Surgery; Senior Medical Director, Insurance Services; Senior Medical Advisor, UPMC Enterprises; US FDA, Special Government Employee; Past President, American Telemedicine Association
  • Jackie Moser, MBA, Director, Digital Health Strategy and Solutions, UPMC Health Plan
  • Caleb Wallace, Esq., MPH, Divisional Chief Legal Officer, VP Health Policy, Contracting & Business Development, UPMC Health Plan

Register Now

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team. The University of Pittsburgh designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Provider is responsible for verifying CME eligibility.


Recent Announcements

Formulary updates effective Jan. 1, 2026

Review upcoming policy and operational updates
Dec. 2025Pharmacy Updates

Voluntary nationwide recall: Famotidine (Fresenius – November)

Fresenius Kabi USA, LLC is recalling three lots (6133156, 6133194, and 6133388) of Famotidine Injection, USP, 20 mg per 2 mL. Famotidine is used to treat excessive secretion of stomach acid or stomach ulcers.
Nov. 2025Pharmacy Updates

Medicaid provider update: High-cost Medicaid drug billing

Billing requirements for Medicaid-covered drugs
Nov. 2025Important Notices